SCIENCE & DEVELOPMENT

Belem Climate COP30: Implement What?

THE climate summit COP30 in Belem, Brazil, where the mighty Amazon River drains into the Atlantic Ocean, formally began on 10 November 2025. The summit has been labeled the “implementation COP,” because of a narrative that, whereas so many promises and commitments have been made earlier, it is necessary to focus on implementation and delivery which are widely recognized to be lagging far behind.

Vaccines, Autism, and Politics of Misinformation

SRIDHAR Vembu, known for the Zoho software and Arattai social media platforms which are being pushed by the ruling dispensation, is also known for his back-to-the-future traditionalist ideas.He recently made the controversial and unsubstantiated claim that childhood vaccines lead to autism. His claim, based on an unreviewed report from the McCullough Foundation, have understandably sparked controversy since  it is clearly based on false information and ignores decades of thorough scientific research that unequivocally shows that vaccines are efficacious, safe and do not cause autism.

Trump’s Trade War: Truce Possible but War Will Continue

The Trump-Xi meeting in South Korea today, 30th October, 2025 may have brought about a temporary relief in the US-China Trade war, but unless we see the fine print of the agreement, it is difficult to assess whether it is a temporary truce or the beginning of a rapprochement. The jury is still out on that one and we will wait for a better understanding of what has really been achieved in Busan South Korea.The hot topic starting with Trump’s second presidential term has been his tariff war, not only with China but with the entire world.

Nobel Prize in Medicine or Physiology: Peacekeepers and Inequities

ON October 6, the announcement of the 2025 Nobel Prize in Physiology or Medicine brought three scientists who had discovered the mechanism of immune system restraint to the attention of the world. Shimon Sakaguchi of Japan, along with Mary Brunkow and Fred Ramsdell of the United States, shared the award. Their findings identified a group of guardian cells that maintain peace within the body, preventing our immune system from attacking our own cells.

Another Blow to Novartis and Its Patent Monopolies

THE Swiss multinational Novartis and the Indian Patent Office are in the news again, as is Section 3(d) of India's Patent Act. Under the 3(d) provision, the Patent Office struck down the Novartis patent on Vymada, a heart failure drug, for lacking either novelty or an inventive step. Vymada, internationally marketed as Entresto, is a combination of two drugs: sacubitril and valsartan, and Novartis was claiming that by mixing the two, it created a "supramolecular complex", a claim rejected by the Indian Patent Office.

Writing the Human Genome

A BOLD new project has been recently announced by a strong group of UK universities supported by the Wellcome Trust, which has more than £1 billion in funds. Its objective is to synthesise the human genome, or in other words, to write what is called the code of life. With an initial investment of £10 million, the Synthetic Human Genome Project (SynHG) aims to create the means to construct human chromosomes – and eventually entire genomes – from the ground up.

Pages

Subscribe to RSS - SCIENCE & DEVELOPMENT